N Lycke

Summary

Country: Sweden

Publications

  1. ncbi request reprint From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance
    Nils Lycke
    Department of Clinical Immunology, University of Goteborg, Guldhedsgatan 10A, S41346 Göteborg, Sweden
    Immunol Lett 97:193-8. 2005
  2. pmc Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity
    John G Nedrud
    Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America
    PLoS ONE 8:e83321. 2013
  3. pmc The role of Peyer's patches in synchronizing gut IgA responses
    Nils Y Lycke
    Mucosal Immunobiology and Vaccines Center, Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg Gothenburg, Sweden
    Front Immunol 3:329. 2012
  4. pmc The female lower genital tract is a privileged compartment with IL-10 producing dendritic cells and poor Th1 immunity following Chlamydia trachomatis infection
    Ellen Marks
    Department of Microbiology and Immunology, Mucosal Immunobiology and Vaccine Center, Institute of Biomedicine, The University of Gothenburg, Gothenburg, Sweden
    PLoS Pathog 6:e1001179. 2010
  5. doi request reprint Recent progress in mucosal vaccine development: potential and limitations
    Nils Lycke
    Center for Mucosal Immunobiology and Vaccines MIVAC, Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Sweden
    Nat Rev Immunol 12:592-605. 2012
  6. ncbi request reprint ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity
    Nils Lycke
    Department of Clinical Immunology, University of Goteborg, S413 46 Göteborg, Sweden
    Ann N Y Acad Sci 1029:193-208. 2004
  7. ncbi request reprint Targeted vaccine adjuvants based on modified cholera toxin
    Nils Lycke
    Department of Clinical Immunology, University of Goteborg, S413 46 Göteborg, Sweden
    Curr Mol Med 5:591-7. 2005
  8. doi request reprint Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins
    N Lycke
    MIVAC, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
    Mucosal Immunol 3:556-66. 2010
  9. ncbi request reprint From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM
    Nils Lycke
    Department of Clinical Immunology, University of Goteborg, S413 46 Göteborg, Sweden
    Cell Microbiol 6:23-32. 2004
  10. ncbi request reprint Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection
    N Lycke
    Department of Medical Microbiology and Immunology, University of Goteborg, Sweden
    J Immunol 163:913-9. 1999

Collaborators

Detail Information

Publications33

  1. ncbi request reprint From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance
    Nils Lycke
    Department of Clinical Immunology, University of Goteborg, Guldhedsgatan 10A, S41346 Göteborg, Sweden
    Immunol Lett 97:193-8. 2005
    ..Therefore, targeting to APC in the absence or presence of the CTA1-enzyme appears to be an effective means to control tolerance and active protective IgA immunity...
  2. pmc Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity
    John G Nedrud
    Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America
    PLoS ONE 8:e83321. 2013
    ..pylori infection based on well selected protective epitopes from relevant antigens incorporated into the CTA1-DD adjuvant platform. ..
  3. pmc The role of Peyer's patches in synchronizing gut IgA responses
    Nils Y Lycke
    Mucosal Immunobiology and Vaccines Center, Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg Gothenburg, Sweden
    Front Immunol 3:329. 2012
    ....
  4. pmc The female lower genital tract is a privileged compartment with IL-10 producing dendritic cells and poor Th1 immunity following Chlamydia trachomatis infection
    Ellen Marks
    Department of Microbiology and Immunology, Mucosal Immunobiology and Vaccine Center, Institute of Biomedicine, The University of Gothenburg, Gothenburg, Sweden
    PLoS Pathog 6:e1001179. 2010
    ..Unexpectedly, the major source of IL-10 was CD11c(+) CD11b(+) DC, probably creating an anti-inflammatory privileged site in the LGT...
  5. doi request reprint Recent progress in mucosal vaccine development: potential and limitations
    Nils Lycke
    Center for Mucosal Immunobiology and Vaccines MIVAC, Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Sweden
    Nat Rev Immunol 12:592-605. 2012
    ..Here, I discuss the expanding knowledge and strategies used in the development of mucosal vaccines...
  6. ncbi request reprint ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity
    Nils Lycke
    Department of Clinical Immunology, University of Goteborg, S413 46 Göteborg, Sweden
    Ann N Y Acad Sci 1029:193-208. 2004
    ..For example, the expression of CD86 in vivo was a prominent feature of the enzymatically active CT or CTA1-DD adjuvants. By contrast, CD80 expression appeared not to be important in CTA1-augmented APCs for an adjuvant function...
  7. ncbi request reprint Targeted vaccine adjuvants based on modified cholera toxin
    Nils Lycke
    Department of Clinical Immunology, University of Goteborg, S413 46 Göteborg, Sweden
    Curr Mol Med 5:591-7. 2005
    ....
  8. doi request reprint Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins
    N Lycke
    MIVAC, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
    Mucosal Immunol 3:556-66. 2010
    ....
  9. ncbi request reprint From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM
    Nils Lycke
    Department of Clinical Immunology, University of Goteborg, S413 46 Göteborg, Sweden
    Cell Microbiol 6:23-32. 2004
    ..Thus, we have demonstrated that rationally designed vectors consisting of CTA1-DD and ISCOMS may provide a novel strategy for the generation of potent and safe mucosal vaccines...
  10. ncbi request reprint Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection
    N Lycke
    Department of Medical Microbiology and Immunology, University of Goteborg, Sweden
    J Immunol 163:913-9. 1999
    ..This study unequivocally demonstrates a direct relationship between mucosal transport of secretory SIgA and intestinal immune protection...
  11. ncbi request reprint The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses
    N Lycke
    Department of Clinical Immunology, University of Goteborg, S 413 46 Goteborg, Sweden
    Curr Opin Mol Ther 3:37-44. 2001
    ..The enhancing effect is associated with enlarged germinal centers, and binding of CTA1-DD to the B-cells strongly upregulates co-stimulatory molecules and counteracts apoptosis by inducing intracellular Bcl-2...
  12. ncbi request reprint The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity
    N Lycke
    Department of Clinical Immunology, University of Goteborg, S 413 46, Goteborg, Sweden
    Vaccine 19:2542-8. 2001
    ..These results support the notion that the CTA1-DD adjuvant can repeatedly be used in the clinic without loss of efficacy even when pre-existing anti-CTA1 antibody levels are high...
  13. ncbi request reprint The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization
    A A Akhiani
    Department of Clinical Immunology, Goteborg University, Goteborg, Sweden
    Scand J Immunol 63:97-105. 2006
    ..These findings clearly demonstrate that CTA1-DD adjuvant is a promising candidate to be further exploited in the development of a mucosal vaccine against H. pylori infection...
  14. ncbi request reprint The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability
    A Eriksson
    Department of Clinical Immunology, University of Goteborg, S 413 46, Goteborg, Sweden
    Vaccine 22:185-93. 2003
    ..Collectively our data suggest that CTA1-DD acted via enhanced co-stimulation, which holds promise as to the use of CTA1-DD as a non-toxic adjuvant in future vaccines for human use...
  15. pmc Immunological memory in B-cell-deficient mice conveys long-lasting protection against genital tract infection with Chlamydia trachomatis by rapid recruitment of T cells
    M Johansson
    Department of Medical Microbiology and Immunology, , , Sweden
    Immunology 102:199-208. 2001
    ..Thus, long-term protection in the genital tract against C. trachomatis infection is conveyed by IFN-gamma-producing CD4+ memory T cells, which appear to be maintained in the absence of antibodies and local antigen deposition...
  16. doi request reprint Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation
    Yu Fang
    Department of Microbiology and Immunology, Mucosal Immunobiology and Vaccine Research Center, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
    J Immunol 185:2935-41. 2010
    ....
  17. ncbi request reprint Impaired mucosal immune responses in interleukin 4-targeted mice
    M Vajdy
    Department of Medical Microbiology and Immunology, University of Goteborg, Sweden
    J Exp Med 181:41-53. 1995
    ..Our findings demonstrate that IL-4 and probably functional Th2 cells are required for induction of gut mucosal antibody responses...
  18. ncbi request reprint Strong differential regulation of serum and mucosal IgA responses as revealed in CD28-deficient mice using cholera toxin adjuvant
    Eva Gärdby
    Department of Clinical Immunology, University of Goteborg, Goteborg, Sweden
    J Immunol 170:55-63. 2003
    ..Although CT is known to strongly up-regulate B7-molecules, we have demonstrated that it acts as a potent mucosal adjuvant in the absence of CD28, suggesting that alternative costimulatory pathways are involved...
  19. doi request reprint CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine
    Dubravka Grdic Eliasson
    Department of Microbiology and Immunology, Mucosal Immunology and Vaccine Research Center, Institute of Biomedicine, University of Goteborg, Box 435, 40530 Goteborg, Sweden
    Vaccine 26:1243-52. 2008
    ..This novel CTA1-3M2e-DD fusion protein combines adjuvant and a conserved influenza A antigen in a promising candidate for a universal anti-influenza vaccine...
  20. pmc Surface and gene expression of immunoglobulin E receptors on mast cells and mast-cell numbers in interleukin-4-gene knockout mice
    X J Chen
    Department of Pathology, Institute of Laboratory Medicine, Sahlgrenska University Hospital, Goteborg, Sweden
    Immunology 96:544-50. 1999
    ..This was unexpected in view of previous findings suggesting that IL-4, in concert with stem cell factor and IL-3, stimulates the proliferation and differentiation of mast cells in vitro...
  21. ncbi request reprint Vaccine-induced immunity against Helicobacter pylori infection is impaired in IL-18-deficient mice
    Ali A Akhiani
    Department of Clinical Immunology, Goteborg University, Goteborg, Sweden
    J Immunol 173:3348-56. 2004
    ....
  22. ncbi request reprint Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection
    Ali A Akhiani
    Department of Clinical Immunology, University of Goteborg, Gothenburg, Sweden
    J Immunol 172:5024-33. 2004
    ....
  23. pmc Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection
    Ellen Marks
    Department of Microbiology and Immunology, Mucosal Immunobiology and Vaccine Research Center, Institute of Biomedicine, Gothenburg University, Box 435, 40530 Gothenburg, Sweden
    Infect Immun 75:4638-47. 2007
    ..Both the CD28-deficient and the ICOS-deficient mice demonstrated poor specific antibody production, supporting the fact that antibodies are not needed for protection against genital tract chlamydial infections...
  24. ncbi request reprint A unique population of extrathymically derived alpha beta TCR+CD4-CD8- T cells with regulatory functions dominates the mouse female genital tract
    Martina Johansson
    Department of Clinical Immunology, University of Goteborg, S 413 46 Goteborg, Sweden
    J Immunol 170:1659-66. 2003
    ..A large fraction of the cells expressed CD25 and produced IFN-gamma upon anti-CD3 plus anti-CD28 stimulation, arguing for a strong regulatory role of this novel T cell population in the mouse female genital tract...
  25. ncbi request reprint Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells
    Ali A Akhiani
    Department of Clinical Immunology, University of Goteborg, Goteborg, Sweden
    J Immunol 169:6977-84. 2002
    ..We conclude that IL-12 and Th1 responses are crucial for H. pylori-specific protective immunity...
  26. ncbi request reprint Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin
    Dubravka Grdic
    Department of Clinical Immunology, University of Goteborg, Goteborg, Sweden
    J Immunol 175:5192-202. 2005
    ..These events may explain why CT-conjugated Ag is substantially more immunogenic than Ag admixed with soluble CT and why CTB-conjugated Ag can tolerize immune responses when given orally or at other mucosal sites...
  27. doi request reprint Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis
    Annemarie Hasselberg
    Mucosal Immunobiology and Vaccine Research Center, Department of Microbiology and Immunology, Sahlgrenska Academy, University of Goteborg, Goteborg, Sweden
    Arthritis Rheum 60:1672-82. 2009
    ....
  28. ncbi request reprint Graft mucosal blood flow is reduced prior to histologic evidence of rejection in mouse small bowel transplantation: a murine model
    H Liden
    Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden
    Transplant Proc 35:824-5. 2003
  29. ncbi request reprint Improved design and intranasal delivery of an M2e-based human influenza A vaccine
    Marina De Filette
    Department for Molecular Biomedical Research, VIB Ghent University, FSVM Building, Technologiepark 927, B 9052 Ghent, Zwijnaarde, Belgium
    Vaccine 24:6597-601. 2006
    ..These results show that M2e is a valid and versatile vaccine candidate to protect against any strain of human influenza A...
  30. ncbi request reprint The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection
    Marina De Filette
    DMBR, Ghent University VIB, FSVM Building, Technologiepark 927, B 9052 Ghent Zwijnaarde, Belgium
    Vaccine 24:544-51. 2006
    ..When the vaccine was administered intraperitoneally, the adjuvant improved the M2e antibody titer in circulation, but did not significantly reduce the morbidity...
  31. ncbi request reprint Laser-Doppler flowmetry is reliable for early diagnosis of small-bowel acute rejection in the mouse
    George Dindelegan
    Surgical Clinic No 1, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
    Microsurgery 23:233-8. 2003
    ..Laser-Doppler perfusion in the rejecting intestinal allograft was decreased before onset of histological features of rejection. Mucosal blood flow measured by laser-Doppler could be used as an early indicator of acute rejection in SBT...
  32. ncbi request reprint Facial nerve lesion response; strain differences but no involvement of IFN-gamma, STAT4 or STAT6
    Olle Lidman
    Department of Medicine, Karolinska Institutet, Neuroimmunology Unit, CMM L08 04, Karolinska Hospital, S171 76 Stockholm
    Neuroreport 13:1589-93. 2002
    ....